tegaserod, Zelnorm

NOTE: On March 30, 2007, the FDA notified healthcare professionals and patients that Novartis had agreed to discontinue marketing tegaserod (Zelnorm) for the short-term treatment of women with irritable bowel syndrome with constipation and for patients younger than 65 years of age with chronic constipation. FDA analysis of safety data pooled from 29 clinical trials involving over 18,000 patients showed an excess number of serious cardiovascular adverse events, including angina, heart attacks, and stroke, in patients taking tegaserod (Zelnorm)  compared to patients taking placebo.

Medical and Pharmacy Editor: Jay Marks, M.D.

Pharmacy Author: Emmanuel Saltiel, Pharm.D.
Medical Editor: Jay Marks, M.D.

GENERIC NAME: tegaserod


DRUG CLASS AND MECHANISM: Tegaserod is an oral medication for the treatment of constipation and constipation-predominant irritable bowel syndrome (IBS) in women. IBS is a chronic gastrointestinal disorder characterized by recurrent abdominal pain or discomfort and altered bowel function which may be either constipation or diarrhea. As many as 20% of American adults may suffer from IBS.

Report Problems to the Food and Drug Administration

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.

Pill Finder Tool

Need help identifying pills and medications?
Use the pill identifier tool on RxList.

Back to Medications Index

Health Solutions From Our Sponsors